Open access
Oct 2026
Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study
Abstract Background Immune checkpoint blockade (ICB) improved survival outcomes for patients with metastatic melanoma. Yet up to 65% of patients experience primary resistance and nearly half of initial responders acquire resistance. The clinical utility of ICB is further tempered by frequent immune-related adverse even...
A. Brekner, M. Mengoni, J. Kött et al.
· Journal for ImmunoTherapy of... · 0 citations